Susan D Farrales Nguyen, NP
Nurse Practitioner · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Susan D Farrales Nguyen’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
Drugs they prescribed that Part D paid
$241,690
Pharmacies billed $241,690 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 848) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
809 generic and 39 brand-name prescriptions · $241,690 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 30 | $134,543 | $4,485 |
| Tenofovir Disoproxil | 232 | $21,428 | $92 |
| Entecavir | 522 | $19,105 | $37 |
| Adefovir Dipivoxil | 33 | $18,961 | $575 |
| Lamivudine Hbv | 21 | $11,534 | $549 |
Year by year
| 2024 | 848 | 239 | 0% (0) | 5% | $241,690 |
| 2023 | 784 | 216 | 0% (0) | 5% | $275,808 |
| 2022 | 826 | 252 | 0% (0) | 5% | $270,695 |
| 2021 | 837 | 238 | 0% (0) | 4% | $245,981 |
| 2020 | 838 | 224 | 0% (0) | 4% | $289,956 |
| 2019 | 713 | 194 | 0% (0) | 4% | $246,379 |
| 2018 | 519 | 148 | 0% (0) | 4% | $214,011 |
| 2017 | 282 | 83 | 0% (0) | 35% | $321,902 |
| 2016 | 268 | 83 | 0% (0) | 46% | $171,102 |
| 2015 | 49 | 25 | 0% (0) | 29% | $21,534 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Vemlidy | 32 | $143,845 | $4,495 |
| Adefovir Dipivoxil | 31 | $35,632 | $1,149 |
| Entecavir | 486 | $34,995 | $72 |
| Tenofovir Disoproxil | 206 | $22,910 | $111 |
| Lamivudine Hbv | 20 | $2,698 | $135 |
2022: 5 drugs
| Vemlidy | 35 | $149,587 | $4,274 |
| Adefovir Dipivoxil | 17 | $42,019 | $2,472 |
| Entecavir | 548 | $32,179 | $59 |
| Tenofovir Disoproxil | 193 | $25,348 | $131 |
| Lamivudine Hbv | 25 | $3,279 | $131 |
2021: 5 drugs
| Vemlidy | 27 | $107,005 | $3,963 |
| Adefovir Dipivoxil | 28 | $58,519 | $2,090 |
| Entecavir | 548 | $32,796 | $60 |
| Tenofovir Disoproxil | 193 | $14,869 | $77 |
| Lamivudine Hbv | 29 | $3,972 | $137 |
2020: 5 drugs
| Vemlidy | 22 | $84,730 | $3,851 |
| Entecavir | 521 | $73,094 | $140 |
| Adefovir Dipivoxil | 59 | $64,422 | $1,092 |
| Tenofovir Disoproxil | 180 | $20,742 | $115 |
| Lamivudine Hbv | 42 | $5,386 | $128 |
2019: 5 drugs
| Entecavir | 427 | $71,842 | $168 |
| Adefovir Dipivoxil | 73 | $65,344 | $895 |
| Vemlidy | 13 | $47,272 | $3,636 |
| Tenofovir Disoproxil | 144 | $17,114 | $119 |
| Lamivudine Hbv | 43 | $5,369 | $125 |
2018: 5 drugs
| Adefovir Dipivoxil | 61 | $53,223 | $873 |
| Entecavir | 298 | $52,049 | $175 |
| Tenofovir Disoproxil | 106 | $42,409 | $400 |
| Vemlidy | 11 | $33,678 | $3,062 |
| Lamivudine Hbv | 33 | $7,114 | $216 |
2017: 6 drugs
| Viread | 63 | $137,678 | $2,185 |
| Entecavir | 137 | $74,942 | $547 |
| Humira | 11 | $49,119 | $4,465 |
| Vemlidy | 21 | $27,546 | $1,312 |
| Adefovir Dipivoxil | 27 | $24,576 | $910 |
| Lamivudine Hbv | 17 | $4,440 | $261 |
2016: 10 drugs
| Humira | 16 | $63,951 | $3,997 |
| Entecavir | 17 | $22,308 | $1,312 |
| Lialda | 20 | $19,789 | $989 |
| Asacol Hd | 15 | $10,097 | $673 |
| Mercaptopurine | 25 | $2,620 | $105 |
| Balsalazide Disodium | 14 | $1,778 | $127 |
| Azathioprine | 34 | $1,268 | $37 |
| Sulfasalazine | 17 | $1,078 | $63 |
| Peg 3350-Electrolyte | 19 | $346 | $18 |
| Omeprazole | 11 | $145 | $13 |
Money from drug and device companies
$150 in 2024
| 2024 | 1 | 1 | None | $150 |
| 2023 | 1 | 1 | None | $109 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $150 | 1 payment
|
See the published payment
| Madrigal Pharmaceuticals | Meals · 2024-10-16 | Rezdiffra | $150 |
See earlier years (2023)
2023: $109
| Gilead Sciences | Biktarvy | $109 | 1 payment
|
Professional record
- NPI
- 1497832455
- Licence
- CA NP9825
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 1804 Embarcadero Rd, Palo Alto, CA, 94303
- NPI first listed
- 2006-11-01
- NPI last updated
- 2021-12-30
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.